170 related articles for article (PubMed ID: 7786778)
1. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients.
Cortelezzi A; Sarina B; Cattaneo C; Pomati M; Silvestris I; Soligo D; Calori R; Di Stefano M; Hu C; Monza M; Radelli L; Maiolo AT
Leukemia; 1996 Jul; 10(7):1181-9. PubMed ID: 8684000
[TBL] [Abstract][Full Text] [Related]
3. Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.
Ogata K; Yokose N; Ito T; An E; Tamura H; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Nomura T
Br J Haematol; 1994 Mar; 86(3):562-7. PubMed ID: 8043438
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21 differentially affects human natural killer cell subsets.
Wendt K; Wilk E; Buyny S; Schmidt RE; Jacobs R
Immunology; 2007 Dec; 122(4):486-95. PubMed ID: 17635612
[TBL] [Abstract][Full Text] [Related]
6. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.
Tripp CS; Wolf SF; Unanue ER
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3725-9. PubMed ID: 8097322
[TBL] [Abstract][Full Text] [Related]
8. Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients.
Mirjačić Martinović K; Babović N; Džodić R; Jurišić V; Matković S; Konjević G
J Transl Med; 2015 Apr; 13():120. PubMed ID: 25889680
[TBL] [Abstract][Full Text] [Related]
9. Human alveolar macrophages augment natural killer cell stimulatory factor (interleukin-12)-inducible killer activity from autologous blood lymphocytes.
Haku T; Sone S; Nabioullin R; Ogura T
Jpn J Cancer Res; 1995 Jan; 86(1):81-7. PubMed ID: 7737914
[TBL] [Abstract][Full Text] [Related]
10. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
11. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
Bennett IM; Zatsepina O; Zamai L; Azzoni L; Mikheeva T; Perussia B
J Exp Med; 1996 Nov; 184(5):1845-56. PubMed ID: 8920872
[TBL] [Abstract][Full Text] [Related]
12. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
13. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
[TBL] [Abstract][Full Text] [Related]
15. The CySF-L2 factor from dialysable human leucocyte extract activates natural killer cytotoxicity by induction of interferon gamma.
Doelker I; Anderer FA
Cancer Immunol Immunother; 1992; 34(5):299-305. PubMed ID: 1540976
[TBL] [Abstract][Full Text] [Related]
16. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration.
Orange JS; Wang B; Terhorst C; Biron CA
J Exp Med; 1995 Oct; 182(4):1045-56. PubMed ID: 7561678
[TBL] [Abstract][Full Text] [Related]
17. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes.
Okabe M; Minagawa T; Nakane A; Sakurada K; Miyazaki T
Scand J Haematol; 1986 Aug; 37(2):111-7. PubMed ID: 3489981
[TBL] [Abstract][Full Text] [Related]
18. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
19. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
Galvani DW; Nethersell AB; Cawley JC
Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
[TBL] [Abstract][Full Text] [Related]
20. Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells.
Poznanski SM; Lee AJ; Nham T; Lusty E; Larché MJ; Lee DA; Ashkar AA
J Innate Immun; 2017; 9(5):511-525. PubMed ID: 28633138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
